Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Bellevue Group AG

Bellevue Group AG cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 32.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 293,621 shares of the medical equipment provider's stock after selling 139,184 shares during the quarter. Bellevue Group AG owned about 0.15% of Zimmer Biomet worth $31,015,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Dodge & Cox lifted its holdings in shares of Zimmer Biomet by 12.0% during the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock valued at $2,019,480,000 after purchasing an additional 2,044,645 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Zimmer Biomet by 1.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider's stock worth $1,559,147,000 after acquiring an additional 176,337 shares during the last quarter. Van ECK Associates Corp boosted its stake in Zimmer Biomet by 5.9% in the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after purchasing an additional 218,688 shares in the last quarter. Franklin Resources Inc. grew its position in Zimmer Biomet by 398.7% during the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock worth $369,469,000 after purchasing an additional 2,796,372 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Zimmer Biomet by 7.6% during the 4th quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider's stock valued at $250,367,000 after purchasing an additional 167,435 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ZBH has been the subject of a number of research analyst reports. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Robert W. Baird dropped their target price on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research report on Tuesday. Wells Fargo & Company reduced their price target on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a research report on Tuesday. BTIG Research reaffirmed a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, Zimmer Biomet has a consensus rating of "Hold" and an average target price of $115.50.

Zimmer Biomet Trading Up 2.2 %

Shares of NYSE ZBH traded up $1.96 during mid-day trading on Tuesday, reaching $92.44. 4,203,120 shares of the company's stock were exchanged, compared to its average volume of 1,695,643. The firm has a market capitalization of $18.29 billion, a price-to-earnings ratio of 20.77, a PEG ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.92 and a 52-week high of $122.25. The company's 50-day moving average is $105.01 and its 200-day moving average is $106.32. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The business had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. During the same period in the previous year, the firm earned $1.94 EPS. The business's revenue was up 1.1% on a year-over-year basis. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.04%. The ex-dividend date of this dividend was Monday, March 31st. Zimmer Biomet's payout ratio is 21.57%.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.95% of the stock is currently owned by company insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.